Targeted Antigens of CAR-T Cell Therapy Information
Target General Information | Top | ||||
---|---|---|---|---|---|
Target ID | T14597 | Target Info | |||
Target Name | Erbb2 tyrosine kinase receptor (HER2) | ||||
Synonyms | p185erbB2; Tyrosine kinase-type cell surface receptor HER2; Receptor tyrosine-protein kinase erbB-2; Proto-oncogene c-ErbB-2; Proto-oncogene Neu; NGL; NEU; Metastatic lymph node gene 19 protein; MLN19; MLN 19; HER2; CD340 | ||||
Target Type | Successful Target | ||||
Gene Name | ERBB2 | ||||
Biochemical Class | Kinase | ||||
UniProt ID |
Targeted Antigens of CAR-T Cell Therapy | Top | ||||
---|---|---|---|---|---|
CAR T-Cell Therapy Drug(s) | Anti-HER2 CAR-T | Drug Info | Phase 1/2 | Pancreatic cancer | [1] |
CART-HER-2 | Drug Info | Phase 1/2 | Solid tumour/cancer | [2] | |
HER-2-targeting CAR T Cells | Drug Info | Phase 1/2 | Breast cancer | [3] | |
CAR-T Cells targeting HER2 | Drug Info | Phase 1 | Pancreatic cancer | [4] | |
CAR-T cells targeting HER2 | Drug Info | Phase 1 | Solid tumour/cancer | [5] | |
HER2-CAR T Cells | Drug Info | Phase 1 | Metastatic malignant neoplasm | [6] | |
HER2-specific CAR T cell | Drug Info | Phase 1 | Pineoblastoma | [7] | |
HER2-specific T cells | Drug Info | Phase 1 | Recurrent glioblastoma | [8] | |
MB-103 | Drug Info | Phase 1 | Glioblastoma multiforme | [9] |
References | Top | ||||
---|---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02713984) A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | ||||
REF 2 | ClinicalTrials.gov (NCT01935843) Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors | ||||
REF 3 | ClinicalTrials.gov (NCT02547961) Chimeric Antigen Receptor-Modified T Cells for Breast Cancer | ||||
REF 4 | ClinicalTrials.gov (NCT03267173) Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. | ||||
REF 5 | ClinicalTrials.gov (NCT03198052) HER2/Mesothelin/Lewis-Y/PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers | ||||
REF 6 | ClinicalTrials.gov (NCT03696030) HER2-CAR T Cells in Treating Participants With Brain or Leptomeningeal Metastases | ||||
REF 7 | ClinicalTrials.gov (NCT03500991) HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors | ||||
REF 8 | ClinicalTrials.gov (NCT02442297) T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma | ||||
REF 9 | ClinicalTrials.gov (NCT03696030) HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases. U.S. National Institutes of Health. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.